Klinische Studien

Für Patienten

In unserem Studienzentrum liegt der Schwerpunkt auf Studien der Phase II und III.

aktuelle klinische Studien zu folgenden Indikationen:

Prostatakarzinom
A confirmatory, prospective, open-label, single-arm, reader-blinded, multi-centre phase 3 study to assess the diagnostic accuracy of Ferumoxtran-10-enhanced Magnetic Resonance Imaging (MRI) and unenhanced MRI in reference to histopathology in newly-diagnosed prostate cancer (PCA) patients, scheduled for radical prostatectomy (RP) wih extended pelvic lymph node dissection (ePLND)	SPL-01-001
An open-label, multicentre, single arm study to assess the efficacy and safety of triptorelin 6-month formulation administered subcutaneously in participants with locally advanced and/or metastatic prostate cancer previously treated and castrated with a GnRH analogue	Triptoswitch
Urothelkarzinom (Harnblase)
A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer	Keynote-B15
Urothelkarzinom (Harnblase und oberer Harntrakt)
Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer	CLIN2001 UCM301
Nierenzellkarzinom
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)	MK6482-022

weitere Informationen finden Sie unter: ClinicalTrials.gov

Sofern Sie in diesem Zusammenhang Fragen haben oder eventuell an einer der Studien in unserer Klinik teilnehmen möchten, setzen Sie sich bitte mit uns in Verbindung.

Kontakt:

Klinische Studien

Pit Raupach